Subscribe To
BIVI / BioVie's degenerative dementia drug candidate to be presented at psychiatry conference
Content Topics
Biovie
Degenerative
Dementia
Drug
Candidate
Presented
Biovie s
Psychiatry
Conference
Stock
BIVI
BIVI News
By Proactive Investors
October 25, 2023
BioVie says blinded data points to hopeful Alzheimer's treatment potential
BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its more_horizontal
By Zacks Investment Research
October 19, 2023
New Strong Buy Stocks for October 19th
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023. more_horizontal
By Proactive Investors
September 26, 2023
BioVie complements its Alzheimer's clinical research program with social impact initiatives
What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is more_horizontal
By Proactive Investors
September 26, 2023
BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end
BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in more_horizontal
By Proactive Investors
September 11, 2023
BioVie presents Alzheimer's study data on patient's baseline characteristics
BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer more_horizontal
By Benzinga
September 6, 2023
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal
By Zacks Investment Research
August 30, 2023
Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical m more_horizontal
By Zacks Investment Research
August 28, 2023
Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with str more_horizontal